XML 16 R5.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Preferred Stock [Member]
Common Stock
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Total
Balance at beginning of period at Dec. 31, 2017   $ 7 $ 44,560 $ (31,542) $ 13,025
Balance at beginning of period (in shares) at Dec. 31, 2017 4,935 679,774      
Increase (Decrease) in Stockholders' Equity          
Net loss       (2,439) (2,439)
Conversion of preferred stock into common stock   $ 4 (4)    
Conversion of preferred stock into common stock (in shares) (4,888) 431,022      
Issuance of common stock in connection with purchase agreements   $ 1 617   618
Issuance of common stock in connection with purchase agreements (in shares)   59,457      
Issuance of common stock in exchange for cancelation of other current liabilities   $ 1 1,896   1,897
Issuance of common stock in exchange for cancelation of other current liabilities (in shares)   120,983      
Issuance of common stock upon exercise of warrants     225   225
Issuance of common stock upon exercise of warrants (in shares)   20,000      
Stock-based compensation     82   82
Balance at end of period at Mar. 31, 2018   $ 13 47,376 (33,981) 13,408
Balance at end of period (in shares) at Mar. 31, 2018 47 1,311,236      
Balance at beginning of period at Dec. 31, 2017   $ 7 44,560 (31,542) 13,025
Balance at beginning of period (in shares) at Dec. 31, 2017 4,935 679,774      
Increase (Decrease) in Stockholders' Equity          
Net loss         (5,270)
Conversion of convertible notes into common stock (in shares)   212,733      
Balance at end of period at Jun. 30, 2018   $ 15 49,455 (37,272) 12,198
Balance at end of period (in shares) at Jun. 30, 2018 47 1,503,969      
Balance at beginning of period at Mar. 31, 2018   $ 13 47,376 (33,981) 13,408
Balance at beginning of period (in shares) at Mar. 31, 2018 47 1,311,236      
Increase (Decrease) in Stockholders' Equity          
Net loss       (2,831) (2,831)
Conversion of convertible notes into common stock (in shares)   192,733      
Issuance of common stock upon exercise of warrants   $ 2 865   867
Issuance of common stock upon exercise of warrants (in shares)   192,733      
Write-off debt derivative liability in conjunction with convertible note conversions         438
Beneficial conversion feature on issuance of notes     1,076   1,076
Liability recorded related to equity purchase agreement repricing       (460) (460)
Stock-based compensation     138   138
Balance at end of period at Jun. 30, 2018   $ 15 49,455 (37,272) 12,198
Balance at end of period (in shares) at Jun. 30, 2018 47 1,503,969      
Balance at beginning of period at Dec. 31, 2018   $ 23 [1] 53,796 (47,696) 6,123
Balance at beginning of period (in shares) at Dec. 31, 2018 47 2,298,738 [1]      
Increase (Decrease) in Stockholders' Equity          
Net loss       (1,652) (1,652)
Conversion of convertible notes into common stock   $ 12 [1] 3,114   3,126
Conversion of convertible notes into common stock (in shares) [1]   1,248,115      
Issuance of common stock in connection with purchase agreements   $ 8 [1] 1,718   1,726
Issuance of common stock in connection with purchase agreements (in shares) [1]   758,076      
Write-off debt premiums (net of debt discounts) in conjunction with convertible note conversions     315   315
Write-off debt derivative liability in conjunction with convertible note conversions     39   39
Stock-based compensation     156   156
Balance at end of period at Mar. 31, 2019   $ 43 [1] 59,138 (49,348) 9,833
Balance at end of period (in shares) at Mar. 31, 2019 47 4,304,929 [1]      
Balance at beginning of period at Dec. 31, 2018   $ 23 [1] 53,796 (47,696) 6,123
Balance at beginning of period (in shares) at Dec. 31, 2018 47 2,298,738 [1]      
Increase (Decrease) in Stockholders' Equity          
Net loss         (7,565)
Conversion of warrants into stock (in shares)   2,386,425      
Balance at end of period at Jun. 30, 2019   $ 60 [1] 69,428 (55,261) 14,227
Balance at end of period (in shares) at Jun. 30, 2019 47 5,993,368 [1]      
Balance at beginning of period at Mar. 31, 2019   $ 43 [1] 59,138 (49,348) 9,833
Balance at beginning of period (in shares) at Mar. 31, 2019 47 4,304,929 [1]      
Increase (Decrease) in Stockholders' Equity          
Net loss       (5,913) (5,913)
Conversion of warrants into stock (in shares)   1,138,310      
Conversion of convertible notes into common stock   $ 12 [1] 4,134   4,146
Conversion of convertible notes into common stock (in shares) [1]   1,138,310      
Issuance of common stock in connection with purchase agreements   $ 2 [1] 682   684
Issuance of common stock in connection with purchase agreements (in shares) [1]   240,000      
Write-off debt premiums (net of debt discounts) in conjunction with convertible note conversions     (842)   (842)
Write-off debt derivative liability in conjunction with convertible note conversions     438    
Proceeds upon issuance of common stock from exercise of warrants   $ 3 [1] 1,572   1,575
Proceeds upon issuance of common stock from exercise of warrants (in shares) [1]   310,200      
Write-off warrant liability in conjunction with warrant exercises     2,364   2,364
Beneficial conversion feature on issuance of notes     1,792   1,792
Stock-based compensation     151   151
Payment of fractional common shares in conjunction with reverse stock split     (1)   (1)
Payment of fractional common shares in conjunction with reverse stock split (in shares) [1]   (71)      
Balance at end of period at Jun. 30, 2019   $ 60 [1] $ 69,428 $ (55,261) $ 14,227
Balance at end of period (in shares) at Jun. 30, 2019 47 5,993,368 [1]      
[1] The common stock shares and additional paid-in capital for all periods presented reflect the one-for fifteen reverse stock split, which took effect on April 26, 2019.